Free Trial
NASDAQ:PASG

Passage Bio (PASG) Stock Price, News & Analysis

Passage Bio logo
$0.62
-0.01 (-1.60%)
(As of 10/31/2024 ET)

About Passage Bio Stock (NASDAQ:PASG)

Key Stats

Today's Range
$0.59
$0.63
50-Day Range
$0.57
$0.82
52-Week Range
$0.54
$1.79
Volume
127,266 shs
Average Volume
267,318 shs
Market Capitalization
$37.91 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$8.33
Consensus Rating
Buy

Company Overview

Passage Bio, Inc., a genetic medicines company, develops gene therapies for central nervous system diseases. It develops PBGM01, a functional GLB1 gene encoding ß-galactosidase for infantile GM1; PBFT02, a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD caused by progranulin deficiency; and PBKR03, a functional GALC gene encoding the hydrolytic enzyme galactosylceramidase for infantile Krabbe disease. The company develops PBML04 for the treatment of metachromatic leukodystrophy; PBAL05 for the treatment of amyotrophic lateral sclerosis; and other program for huntington's disease. It has a strategic research collaboration with the Trustees of the University of Pennsylvania's Gene Therapy Program; and collaboration agreement, and a development services and clinical supply agreement with Catalent Maryland, Inc. Passage Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.

Passage Bio Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
63rd Percentile Overall Score

PASG MarketRank™: 

Passage Bio scored higher than 63% of companies evaluated by MarketBeat, and ranked 444th out of 997 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Passage Bio has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Passage Bio has only been the subject of 1 research reports in the past 90 days.

  • Read more about Passage Bio's stock forecast and price target.
  • Earnings Growth

    Earnings for Passage Bio are expected to grow in the coming year, from ($0.94) to ($0.67) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Passage Bio is -0.46, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Passage Bio is -0.46, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Passage Bio has a P/B Ratio of 0.31. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about Passage Bio's valuation and earnings.
  • Percentage of Shares Shorted

    3.28% of the float of Passage Bio has been sold short.
  • Short Interest Ratio / Days to Cover

    Passage Bio has a short interest ratio ("days to cover") of 5.7.
  • Change versus previous month

    Short interest in Passage Bio has recently decreased by 1.18%, indicating that investor sentiment is improving.
  • Dividend Yield

    Passage Bio does not currently pay a dividend.

  • Dividend Growth

    Passage Bio does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    3.28% of the float of Passage Bio has been sold short.
  • Short Interest Ratio / Days to Cover

    Passage Bio has a short interest ratio ("days to cover") of 5.7.
  • Change versus previous month

    Short interest in Passage Bio has recently decreased by 1.18%, indicating that investor sentiment is improving.
  • News Sentiment

    Passage Bio has a news sentiment score of 0.38. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.68 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 3 news articles for Passage Bio this week, compared to 1 article on an average week.
  • Search Interest

    10 people have searched for PASG on MarketBeat in the last 30 days. This is an increase of 900% compared to the previous 30 days.
  • MarketBeat Follows

    Only 1 people have added Passage Bio to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Passage Bio insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $65,405.00 in company stock.

  • Percentage Held by Insiders

    Only 4.30% of the stock of Passage Bio is held by insiders.

  • Percentage Held by Institutions

    53.48% of the stock of Passage Bio is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Passage Bio's insider trading history.
Receive PASG Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Passage Bio and its competitors with MarketBeat's FREE daily newsletter.

PASG Stock News Headlines

Passage Bio delivered preclinical, interim data at ESGCT
The real reason Elon is fully endorsing Trump
Elon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to humanity, there is a war being waged on Elon Musk. This war has nothing to do with X, Elon’s stance on immigration or his support for Donald Trump.
See More Headlines

PASG Stock Analysis - Frequently Asked Questions

Passage Bio's stock was trading at $1.01 at the beginning of 2024. Since then, PASG shares have decreased by 38.6% and is now trading at $0.6199.
View the best growth stocks for 2024 here
.

Passage Bio, Inc. (NASDAQ:PASG) announced its quarterly earnings data on Thursday, August, 8th. The company reported ($0.26) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.31) by $0.05.

Passage Bio (PASG) raised $126 million in an initial public offering (IPO) on Friday, February 28th 2020. The company issued 7,400,000 shares at a price of $16.00-$18.00 per share. J.P. Morgan, Goldman Sachs and Cowen acted as the underwriters for the IPO and Chardan was co-manager.

Shares of PASG stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Passage Bio investors own include Enovix (ENVX), Ginkgo Bioworks (DNA), COMPASS Pathways (CMPS), Rambus (RMBS), Toast (TOST), Globant (GLOB) and Luminar Technologies (LAZR).

Company Calendar

Last Earnings
8/08/2024
Today
10/31/2024
Next Earnings (Estimated)
11/11/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:PASG
Fax
N/A
Employees
130
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$8.33
High Stock Price Target
$13.00
Low Stock Price Target
$5.00
Potential Upside/Downside
+1,279.2%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
$-102,060,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$2.03 per share

Miscellaneous

Free Float
59,111,000
Market Cap
$37.24 million
Optionable
Optionable
Beta
1.19
12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

This page (NASDAQ:PASG) was last updated on 10/31/2024 by MarketBeat.com Staff
From Our Partners